Last updated: February 14, 2026
Overview of the Drug
NDC 57237-0240 refers to Lutathera (lutetium Lu 177 dotatate), a radiolabeled therapy used in the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Approved by the FDA in January 2018, Lutathera is administered intravenously and involves peptide receptor radionuclide therapy (PRRT). It targets tumors expressing somatostatin receptors with a beta-emitting isotope, lutetium-177, delivering targeted radiation.
Market Size and Demand Drivers
The GEP-NETs market is characterized by increasing diagnosis rates. The incidence of neuroendocrine tumors has increased from approximately 5 cases per 100,000 in the 1970s to around 7.8 cases per 100,000 in recent years [1].
Global neuroendocrine tumor (NET) therapy market was valued at approximately $500 million in 2022 and is projected to reach over $1 billion by 2030, with a compound annual growth rate (CAGR) of roughly 11-13% [2].
Lutathera covers a portion of this market, primarily targeting the segment with well-differentiated, somatostatin receptor-positive tumors. Its usage is limited by prior treatments, patient health, and receptor expression levels.
Competitive Landscape
Lutathera holds a near-monopoly in PRRT for GEP-NETs since FDA approval. Its main competitors include:
-
Octreotide and Lanreotide: Long-acting somatostatin analogs used for symptom control and tumor stabilization, not direct radiotherapy.
-
Experimental and External Radioligand Therapies: Emerging therapies from companies like Advanced Accelerator Applications (part of Novartis), Orano Med, and others.
-
Off-label uses of existing radiopharmaceuticals.
The standard of care in this niche makes Lutathera a dominant player, but competition is expected from new entrants aiming to improve efficacy, reduce costs, and expand indications.
Pricing and Cost Structure
The wholesale acquisition cost (WAC) for Lutathera is approximately $30,000 per dose (single treatment cycle), with typically four cycles administered. The average treatment course costs about $120,000 [3].
Patient Access Programs and insurance coverage significantly influence net prices and reimbursement. The Centers for Medicare & Medicaid Services (CMS) reimburses via Diagnosis-Related Group (DRG) codes and other mechanisms, usually covering most treatment costs.
Pricing Trends and Projections
The initial launch price for Lutathera reflects the cost of manufacturing, R&D recovery, and market positioning, subject to inflation adjustments, payer negotiations, and policy shifts.
Key projections:
-
Short-term (2023-2025): The price per dose remains stable at approximately $30,000, with minor adjustments for inflation and negotiations.
-
Mid-term (2026-2030): Price increases could average 2-3% annually, aligning with inflation and cost of goods. Introduction of second-generation radioligands or biosimilars could influence prices.
-
Potential Future Trends: Payers may seek discounts or value-based arrangements, especially if new therapies demonstrate superior efficacy or safety. Price reductions of 10-15% might occur if biosimilars or alternative treatments gain market share.
Regulatory and Reimbursement Factors
- FDA approval solidifies Lutathera’s market position.
- Reimbursement policies via CMS and commercial payers dominate pricing landscape.
- Legislative developments targeting drug pricing transparency and value-based pricing could pressure prices downward.
Market Penetration and Adoption
Adoption rates currently high among specialized centers, with approximately 2,500 patients treated since launch. The expansion into broader populations depends on:
- Regulatory expansions for additional tumor types.
- Evidence of improved survival and quality of life.
- Expansion into emerging markets (Europe, Asia).
Key Risks
- Entry of competing radioligand therapies.
- Reimbursement caps and regulatory constraints.
- Manufacturing costs and supply chain disruptions.
Summary
| Aspect |
Details |
| Market size (2023) |
~$600 million globally |
| Treatment cost per patient |
~$120,000 (4 cycles) |
| Price per dose |
~$30,000 |
| Projected CAGR (2023-2030) |
10-12% (market growth) |
| Price trend |
Stable short-term, slight increases (~2-3%) expected |
Key Takeaways
- NDC 57237-0240 (Lutathera) is the leading radiolabeled therapy for GEP-NETs, with a dominant market share.
- The global market is growing due to increased diagnosis and expanding indications.
- Pricing remains stable in the short term at about $30,000 per dose, with moderate increases expected.
- Market expansion faces competition from emerging therapies and biosimilars.
- Reimbursement policies and regulatory environments heavily influence pricing and adoption.
FAQs
1. What factors influence Lutathera’s pricing?
Market demand, manufacturing costs, reimbursement negotiations, competition, and regulatory changes.
2. How does Lutathera compare with alternative treatments?
It offers targeted radiotherapy with proven efficacy in small patient populations; alternatives mainly include somatostatin analogs and experimental therapies.
3. What are the main barriers to market growth?
Limited indication expansion, high treatment costs, and payer restrictions.
4. Are biosimilars likely to impact Lutathera’s price?
Potentially, if biosimilars meet regulatory standards and demonstrate comparable efficacy, prices could decrease by 10-15%.
5. What is the outlook for future regulatory approvals?
Possible approvals for additional tumor types or combination therapies could broaden market potential, influencing demand and pricing.
Citations
[1] Rindi G, et al. "Epidemiology of neuroendocrine tumors." Endocrine-Related Cancer, 2018.
[2] Research and Markets. "Neuroendocrine Tumors (NET) Therapy Market Analysis." 2022.
[3] GoodRx. "Lutathera prices and reimbursement info." 2022.
